Scalable revenue cycle ecosystem designed to support anticipated billing volumes; CNSide assay billing to begin in Q3 2026 with accumulated 2026 backlog of tests and concurrent case billingHOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has selected XiFin, Inc. (“XiFin”), a market leader in artificial intelligence (AI)-driven revenue cycle management (RCM) for diagnostic prov ...